Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective.

Kloks C, Berger C, Cortez P, Dean Y, Heinrich J, Bjerring Jensen L, Koppenburg V, Kostense S, Kramer D, Spindeldreher S, Kirby H.

J Immunol Methods. 2015 Feb;417:1-9. doi: 10.1016/j.jim.2015.01.003. Epub 2015 Jan 17. Review.

PMID:
25602137
2.

Stability studies of binding and functional anti-vaccine antibodies.

Hendriks J, Stals C, Versteilen A, Mommaas B, Verhoeven M, Tirion F, Haak MT, Ribbens W, Bosch M, Trommel M, Kostense S.

Bioanalysis. 2014 May;6(10):1385-93. doi: 10.4155/bio.14.96.

PMID:
24958122
3.

Preclinical models used for immunogenicity prediction of therapeutic proteins.

Brinks V, Weinbuch D, Baker M, Dean Y, Stas P, Kostense S, Rup B, Jiskoot W.

Pharm Res. 2013 Jul;30(7):1719-28. doi: 10.1007/s11095-013-1062-z. Epub 2013 May 7. Review.

PMID:
23649852
4.

Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples.

Kostense S, Moore S, Companjen A, Bakker AB, Marissen WE, von Eyben R, Weverling GJ, Hanlon C, Goudsmit J.

Antimicrob Agents Chemother. 2012 Jul;56(7):3524-30. doi: 10.1128/AAC.06179-11. Epub 2012 Apr 30.

5.

Challenges of immunogenicity assays for vaccines.

Kostense S, Hendriks J.

Bioanalysis. 2012 Feb;4(4):397-406. doi: 10.4155/bio.11.327. Review.

PMID:
22394140
6.

A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines.

Kostense S, Mommaas B, Hendriks J, Verhoeven M, Ter Haak M, Tirion F, Wiesken E, Pau MG, Radosevic K, Goudsmit J.

Clin Vaccine Immunol. 2011 May;18(5):776-82. doi: 10.1128/CVI.00547-10. Epub 2011 Mar 16.

7.

First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity.

Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, Lagerwerf F, Worst S, van Corven E, Kostense S, Hartmann K, Weverling GJ, Uytdehaag F, Herzog C, Briggs DJ, Rupprecht CE, Grimaldi R, Goudsmit J.

Vaccine. 2008 Nov 5;26(47):5922-7. doi: 10.1016/j.vaccine.2008.08.050. Epub 2008 Sep 17.

PMID:
18804136
8.

A sensitive cell-based assay for the detection of residual infectious West Nile virus.

Koldijk MH, Bogaards JA, Kostense S, de Vocht M, Gijsbers L, Ter Haak M, Ophorst C, Brakenhoff JP, Weverling GJ, Guichoux JY, Uytdehaag F, Lewis J, Goudsmit J, Marzio G.

Vaccine. 2007 Sep 28;25(39-40):6872-81. Epub 2007 Jul 27.

PMID:
17707954
9.

High responsiveness of HLA-B57-restricted Gag-specific CD8+ T cells in vitro may contribute to the protective effect of HLA-B57 in HIV-infection.

Jansen CA, Kostense S, Vandenberghe K, Nanlohy NM, De Cuyper IM, Piriou E, Manting EH, Miedema F, van Baarle D.

Eur J Immunol. 2005 Jan;35(1):150-8.

10.

Characterization of virus-specific CD8(+) effector T cells in the course of HIV-1 infection: longitudinal analyses in slow and rapid progressors.

Jansen CA, Piriou E, Bronke C, Vingerhoed J, Kostense S, van Baarle D, Miedema F.

Clin Immunol. 2004 Dec;113(3):299-309.

PMID:
15507395
11.

An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.

Ophorst OJ, Kostense S, Goudsmit J, De Swart RL, Verhaagh S, Zakhartchouk A, Van Meijer M, Sprangers M, Van Amerongen G, Yüksel S, Osterhaus AD, Havenga MJ.

Vaccine. 2004 Aug 13;22(23-24):3035-44.

PMID:
15297053
12.

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.

Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, Vogels R, Bakker M, Berkhout B, Havenga M, Goudsmit J.

AIDS. 2004 May 21;18(8):1213-6.

PMID:
15166541
13.

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J.

J Immunol. 2004 May 15;172(10):6290-7.

14.

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, Lifton MA, Koudstaal W, Pau MG, Kostense S, Havenga MJ, Goudsmit J, Letvin NL, Barouch DH.

J Virol. 2004 Mar;78(6):2666-73.

15.

Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.

Slager EH, van der Minne CE, Goudsmit J, van Oers JM, Kostense S, Havenga MJ, Osanto S, Griffioen M.

Cancer Gene Ther. 2004 Mar;11(3):227-36.

PMID:
14726960
16.

Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, Goudsmit J, Havenga MJ, Kostense S.

J Clin Microbiol. 2003 Nov;41(11):5046-52.

17.

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M.

J Virol. 2003 Aug;77(15):8263-71.

18.

Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue.

van Baarle D, Kostense S, van Oers MH, Hamann D, Miedema F.

Trends Immunol. 2002 Dec;23(12):586-91. Review.

PMID:
12464570
19.

Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection.

van Baarle D, Kostense S, Hovenkamp E, Ogg G, Nanlohy N, Callan MF, Dukers NH, McMichael AJ, van Oers MH, Miedema F.

AIDS. 2002 Oct 18;16(15):2001-11.

PMID:
12370498
20.

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.

Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, Van Baarle D, Kostense S, Miedema F, McLaughlin M, Ehler L, Metcalf J, Liu S, Connors M.

Nat Immunol. 2002 Nov;3(11):1061-8. Epub 2002 Oct 7.

PMID:
12368910
21.

Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.

Kostense S, Otto SA, Knol GJ, Manting EH, Nanlohy NM, Jansen C, Lange JM, van Oers MH, Miedema F, van Baarle D.

Eur J Immunol. 2002 Apr;32(4):1080-9.

22.

Persistent numbers of tetramer+ CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS.

Kostense S, Vandenberghe K, Joling J, Van Baarle D, Nanlohy N, Manting E, Miedema F.

Blood. 2002 Apr 1;99(7):2505-11.

23.

Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma.

van Baarle D, Hovenkamp E, Callan MF, Wolthers KC, Kostense S, Tan LC, Niesters HG, Osterhaus AD, McMichael AJ, van Oers MH, Miedema F.

Blood. 2001 Jul 1;98(1):146-55.

24.

T cell expansions in lymph nodes and peripheral blood in HIV-1-infected individuals: effect of antiretroviral therapy.

Kostense S, Raaphorst FM, Joling J, Notermans DW, Prins JM, Danner SA, Reiss P, Lange JM, Teale JM, Miedema F.

AIDS. 2001 Jun 15;15(9):1097-107.

PMID:
11416711
25.

High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function.

Kostense S, Ogg GS, Manting EH, Gillespie G, Joling J, Vandenberghe K, Veenhof EZ, van Baarle D, Jurriaans S, Klein MR, Miedema F.

Eur J Immunol. 2001 Mar;31(3):677-86.

26.

Normalization of the CD4 T cell receptor repertoire after evolution of syncytium-inducing HIV-1 variants.

Kostense S, Krop E, Blaak H, Schuitemaker H, Miedema F.

AIDS. 2000 Feb 18;14(3):330-1. No abstract available.

PMID:
10716514
27.

Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression.

Ogg GS, Kostense S, Klein MR, Jurriaans S, Hamann D, McMichael AJ, Miedema F.

J Virol. 1999 Nov;73(11):9153-60.

28.

Evidence that human CD8+CD45RA+CD27- cells are induced by antigen and evolve through extensive rounds of division.

Hamann D, Kostense S, Wolthers KC, Otto SA, Baars PA, Miedema F, van Lier RA.

Int Immunol. 1999 Jul;11(7):1027-33.

PMID:
10383934
29.

Diversity of the T-cell receptor BV repertoire in HIV-1-infected patients reflects the biphasic CD4+ T-cell repopulation kinetics during highly active antiretroviral therapy.

Kostense S, Raaphorst FM, Notermans DW, Joling J, Hooibrink B, Pakker NG, Danner SA, Teale JM, Miedema F.

AIDS. 1998 Dec 24;12(18):F235-40.

PMID:
9875570
30.

Interleukin 12 administration enhances Th1 activity but delays recovery from influenza A virus infection in mice.

Kostense S, Sun WH, Cottey R, Taylor SF, Harmeling S, Zander D, Small PA Jr, Bender BS.

Antiviral Res. 1998 May;38(2):117-30.

PMID:
9707374

Supplemental Content

Loading ...
Support Center